Literature DB >> 9920077

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

R S Legro1, A R Kunselman, W C Dodson, A Dunaif.   

Abstract

Women with polycystic ovary syndrome (PCOS) are insulin resistant, have insulin secretory defects, and are at high risk for glucose intolerance. We performed this study to determine the prevalence of glucose intolerance and parameters associated with risk for this in PCOS women. Two-hundred and fifty-four PCOS women, aged 14-44 yr, were prospectively evaluated at 2 centers, 1 urban and ethnically diverse (n = 110) and 1 rural and ethnically homogeneous (n = 144). The rural PCOS women were compared to 80 control women of similar weight, ethnicity, and age. A 75-g oral glucose challenge was administered after a 3-day 300-g carbohydrate diet and an overnight fast with 0 and 2 h blood samples for glucose levels. Diabetes was categorized according to WHO criteria. The prevalence of glucose intolerance was 31.1% impaired glucose intolerance (IGT) and 7.5% diabetes. In nonobese PCOS women (body mass index, <27 kg/m2), 10.3% IGT and 1.5% diabetes were found. The prevalence of glucose intolerance was significantly higher in PCOS vs. control women (chi2 = 7.0; P = 0.01; odds ratio = 2.76; 95% confidence interval = 1.23-6.57). Variables most associated with postchallenge glucose levels were fasting glucose levels (P < 0.0001), PCOS status (P = 0.002), waist/hip ratio (P = 0.01), and body mass index (P = 0.021). The American Diabetes Association criteria applied to fasting glucose significantly underdiagnosed diabetes compared to the WHO criteria (3.2% vs. 7.5%; chi2 = 4.7; P = 0.046; odds ratio = 2.48; 95% confidence interval = 1.01-6.69). We conclude that 1) PCOS women are at significantly increased risk for IGT and type 2 diabetes mellitus at all weights and at a young age; 2) these prevalence rates are similar in 2 different populations of PCOS women, suggesting that PCOS may be a more important risk factor than ethnicity or race for glucose intolerance in young women; and 3) the American Diabetes Association diabetes diagnostic criteria failed to detect a significant number of PCOS women with diabetes by postchallenge glucose values.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920077     DOI: 10.1210/jcem.84.1.5393

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  335 in total

Review 1.  Type 2 diabetes in children and youth.

Authors:  Francine Ratner Kaufman
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 3.  PCOS in adolescence and type 2 diabetes.

Authors:  Anne-Marie Carreau; Jean-Patrice Baillargeon
Journal:  Curr Diab Rep       Date:  2015-01       Impact factor: 4.810

4.  Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome.

Authors:  Romana Dmitrovic; Heather I Katcher; Allen R Kunselman; Richard S Legro
Journal:  Obstet Gynecol       Date:  2011-10       Impact factor: 7.661

5.  Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Paulina A Essah; Teimuraz Apridonidze; Andrea Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

6.  Obesity and Polycystic Ovary Syndrome.

Authors:  Susan Sam
Journal:  Obes Manag       Date:  2007-04

Review 7.  Emerging role of testosterone in pancreatic β-cell function and insulin secretion.

Authors:  Weiwei Xu; Jamie Morford; Franck Mauvais-Jarvis
Journal:  J Endocrinol       Date:  2019-01-01       Impact factor: 4.286

8.  Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies.

Authors:  Panagiotis Anagnostis; Rodis D Paparodis; Julia K Bosdou; Christina Bothou; Djuro Macut; Dimitrios G Goulis; Sarantis Livadas
Journal:  Endocrine       Date:  2021-06-26       Impact factor: 3.633

9.  Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria.

Authors:  Miro Šimun Alebić; Tomislav Bulum; Nataša Stojanović; Lea Duvnjak
Journal:  Endocrine       Date:  2014-02-13       Impact factor: 3.633

10.  Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?

Authors:  M Bahceci; A Tuzcu; S Bahceci; S Tuzcu
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.